|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0010711,
umls-concept:C0011015,
umls-concept:C0023467,
umls-concept:C0205390,
umls-concept:C0220825,
umls-concept:C0332283,
umls-concept:C0444956,
umls-concept:C0600558,
umls-concept:C1442989,
umls-concept:C1519429,
umls-concept:C2603343
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-11-7
|
|
pubmed:abstractText |
Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100-200 mg/m(2)/day and an anthracycline. Such combinations produce complete response (CR) rates of 60-80% in patients with de novo AML. On the basis of a previous report, suggesting a higher CR rate using a regimen of standard daunomycin and cytarabine followed by 3 days of high-dose cytarabine (HDAC), 101 eligible patients received this regimen in a phase II trial. Sixty patients [59%, 95% confidence interval (CI) 49-69%] achieved a CR, and 10 patients died of infection during induction. Although cytogenetic risk group affected overall survival (P = 0.0016) and relapse-free survival (P = 0.0043), it had no impact on CR rate (P = 0.63). Patients received postremission therapy with repetitive courses of alternate day high-dose cytarabine; this was associated with considerable toxicity and the majority of patients could not receive all of the scheduled postremission therapy. The estimated median survival was 23 months (95% CI 15-34 months), and the estimated probability of surviving 5 years was 34% (95% CI 24-43%). The results of this intensive induction regimen were similar to that seen in previous trials and were not as promising as reported in the previous pilot study.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA04919,
http://linkedlifedata.com/resource/pubmed/grant/CA04920,
http://linkedlifedata.com/resource/pubmed/grant/CA12213,
http://linkedlifedata.com/resource/pubmed/grant/CA12644,
http://linkedlifedata.com/resource/pubmed/grant/CA16385,
http://linkedlifedata.com/resource/pubmed/grant/CA20319,
http://linkedlifedata.com/resource/pubmed/grant/CA22433,
http://linkedlifedata.com/resource/pubmed/grant/CA28862,
http://linkedlifedata.com/resource/pubmed/grant/CA32102,
http://linkedlifedata.com/resource/pubmed/grant/CA35090,
http://linkedlifedata.com/resource/pubmed/grant/CA35119,
http://linkedlifedata.com/resource/pubmed/grant/CA35128,
http://linkedlifedata.com/resource/pubmed/grant/CA35176,
http://linkedlifedata.com/resource/pubmed/grant/CA35178,
http://linkedlifedata.com/resource/pubmed/grant/CA35192,
http://linkedlifedata.com/resource/pubmed/grant/CA35261,
http://linkedlifedata.com/resource/pubmed/grant/CA35431,
http://linkedlifedata.com/resource/pubmed/grant/CA35996,
http://linkedlifedata.com/resource/pubmed/grant/CA37981,
http://linkedlifedata.com/resource/pubmed/grant/CA38926,
http://linkedlifedata.com/resource/pubmed/grant/CA42777,
http://linkedlifedata.com/resource/pubmed/grant/CA45377,
http://linkedlifedata.com/resource/pubmed/grant/CA45450,
http://linkedlifedata.com/resource/pubmed/grant/CA45807,
http://linkedlifedata.com/resource/pubmed/grant/CA46282,
http://linkedlifedata.com/resource/pubmed/grant/CA46368,
http://linkedlifedata.com/resource/pubmed/grant/CA46441,
http://linkedlifedata.com/resource/pubmed/grant/CA52654,
http://linkedlifedata.com/resource/pubmed/grant/CA58416,
http://linkedlifedata.com/resource/pubmed/grant/CA58658,
http://linkedlifedata.com/resource/pubmed/grant/CA58686,
http://linkedlifedata.com/resource/pubmed/grant/CA58861,
http://linkedlifedata.com/resource/pubmed/grant/CA63845,
http://linkedlifedata.com/resource/pubmed/grant/CA67575,
http://linkedlifedata.com/resource/pubmed/grant/CA76429,
http://linkedlifedata.com/resource/pubmed/grant/CA76462
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0361-8609
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1056-62
|
|
pubmed:meshHeading |
pubmed-meshheading:17696203-Adult,
pubmed-meshheading:17696203-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17696203-Cytarabine,
pubmed-meshheading:17696203-Daunorubicin,
pubmed-meshheading:17696203-Ethnic Groups,
pubmed-meshheading:17696203-Female,
pubmed-meshheading:17696203-Humans,
pubmed-meshheading:17696203-Leukemia, Myeloid, Acute,
pubmed-meshheading:17696203-Male,
pubmed-meshheading:17696203-Middle Aged,
pubmed-meshheading:17696203-Survival Analysis,
pubmed-meshheading:17696203-Time Factors,
pubmed-meshheading:17696203-Treatment Outcome,
pubmed-meshheading:17696203-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
|
|
pubmed:affiliation |
Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington 98109, USA. spetersd@u.washington.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
